BX 001N
Alternative Names: BX-001NLatest Information Update: 18 Dec 2023
At a glance
- Originator Bilix
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Reperfusion injury
Most Recent Events
- 17 Nov 2023 Phase-I clinical trials in Reperfusion injury (In volunteers) in Australia (IV) (NCT06097702)
- 30 Oct 2023 BX 001N is available for licensing as of 30 Oct 2023. https://www.bilix.com/pipeline/
- 27 Oct 2023 Preclinical trials in Reperfusion injury in South Korea (IV)